Skip to main content
Clinical Trials/NCT04136873
NCT04136873
Completed
Phase 1

A Phase 1B Trial To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CVL-231 in Subjects With Schizophrenia

Cerevel Therapeutics, LLC5 sites in 1 country130 target enrollmentOctober 15, 2019

Overview

Phase
Phase 1
Intervention
CVL-231
Conditions
Schizophrenia
Sponsor
Cerevel Therapeutics, LLC
Enrollment
130
Locations
5
Primary Endpoint
Change from Baseline of Simpson-Angus Scale (SAS) Results
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-231 following multiple-dose oral administration in subjects with schizophrenia.

Registry
clinicaltrials.gov
Start Date
October 15, 2019
End Date
June 3, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects with a primary diagnosis of schizophrenia per DSM-5, as confirmed by the MINI.
  • Subjects with the following scores on the PANSS at time of signing ICF and at Day -1: • Positive Subscale 7 (hostility) ≤3 (normal to moderate) • General Psychopathology Subscale 8 (uncooperativeness) ≤3 (normal to moderate)
  • Subjects with the following scores (normal to mild symptoms) at time of signing ICF and at Day -1: • All individual items of the Modified SAS (M-SAS) \<2 • All individual items (Items 1-7) of the Abnormal Involuntary Movement Scale (AIMS) \<2 • Clinical global assessment item of the Barnes Akathisia Rating Scale (BARS) \<3
  • Body mass index of 17.5 to 38.0 kg/m2 and a total body weight \>50 kg (110 lbs).
  • Cohorts 1 Through 5 (Part A):
  • Subjects are eligible to be included in trial (Cohorts 1 through 5) only if all of the following additional criteria apply:
  • Male and female subjects, ages 18 to 50 years, inclusive.
  • Subjects with a score on the CGI-S ≤4 (normal to moderately ill) at time of signing ICF and at Day -
  • Subjects with a PANSS total score of ≤80 at the time of signing ICF and at Day -
  • Cohort 6 (Part B):

Exclusion Criteria

  • Subjects with a current DSM-5 diagnosis other than schizophrenia including, but not limited to, mental retardation; schizoaffective disorder; schizophreniform disorder; psychotic depression; major depressive disorder; bipolar disorder; post-traumatic stress disorder; generalized anxiety disorder, obsessive compulsive disorder, eating disorders (bulimia, anorexia), or other anxiety disorders as a primary diagnosis (subjects with anxiety symptoms secondary to schizophrenia are allowed); delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Subjects with schizophrenia who were considered resistant/refractory to antipsychotic treatment by history or who had a history of failure to respond to clozapine or response to clozapine treatment only.
  • Subjects with EPS being treated with a medication that required dose modification and/or new treatment within 6 months prior to signing ICF.
  • Subjects with a current history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine (including newly diagnosed diabetes mellitus or subjects with known diabetes mellitus with glycosylated hemoglobin (HbA1c)\>7.5%), hematological, immunological, psychiatric (excluding schizophrenia), or neurological disease.
  • Subjects with a current or past history of significant cardiovascular disease.
  • Subjects who experienced acute depressive symptoms within the past 30 days.
  • Subjects with epilepsy or a history of seizures, except for a single seizure episode, eg, a childhood febrile seizure, or a seizure related to trauma or alcohol withdrawal.
  • An active central nervous system infection, demyelinating disease, degenerative neurological disease, mental retardation, or any central nervous system disease deemed to be progressive.
  • History of moderate to severe substance or alcohol-use disorder (excluding nicotine or caffeine) as per DSM-5 criteria within 12 months prior to signing ICF.
  • Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent).

Arms & Interventions

Part A: 5 mg QD CVL-231

Oral Dose

Intervention: CVL-231

Part A: 5 mg QD Placebo

Matching Placebo; Oral Dose

Intervention: Matching Placebo

Part A: 10 mg QD CVL-231

Oral Dose

Intervention: CVL-231

Part A: 10 mg QD Placebo

Matching Placebo; Oral Dose

Intervention: Matching Placebo

Part A: 20 mg QD CVL-231

Oral Dose

Intervention: CVL-231

Part A: 20 mg QD Placebo

Matching Placebo; Oral Dose

Intervention: Matching Placebo

Part A: 5-10-20 mg BID CVL-231

Oral Dose

Intervention: CVL-231

Part A: 5-10-20 mg BID Placebo

Matching Placebo; Oral Dose

Intervention: Matching Placebo

Part A: 30 mg QD CVL-231

Oral Dose

Intervention: CVL-231

Part A: 30 mg QD Placebo

Matching Placebo; Oral Dose

Intervention: Matching Placebo

Part B 30 mg QD CVL-231

Oral Dose

Intervention: CVL-231

Part B 30 mg QD Placebo

Matching Placebo; Oral Dose

Intervention: Matching Placebo

Part B 20 mg BID CVL-231

Oral Dose

Intervention: CVL-231

Part B 20 mg BID Placebo

Intervention: Matching Placebo

Outcomes

Primary Outcomes

Change from Baseline of Simpson-Angus Scale (SAS) Results

Time Frame: Up to Day 72

Evaluating Extrapyramidal symptoms using the SAS. The SAS consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.

Incidence of Treatment Emergent Adverse Events (TEAEs)

Time Frame: Up to Day 72

Includes Incidence of Significant ECG Abnormalities Occurring Post-Baseline, significant changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature), and changes in laboratory measures (hematology, serum chemistry and urinalysis)

Change from Baseline of Abnormal Involuntary Movement Scale (AIMS) Results

Time Frame: Up to Day 72

The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Facial and oral movements (items 1 through 4), extremity movements (items 5 and 6), and trunk movements (item 7) are observed unobtrusively while the subject is at rest, and the investigator also makes global judgments on the subject's dyskinesias (items 8 through 10). Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the subject's dental status. The AIMS Movement Rating Score is defined as the sum of items 1 through 7 (ie, items 1 through 4, facial and oral movements; items 5 and 6, extremity movements; and item 7, trunk movements).

Incidence of suicidality as assessed by Columbia-Suicide Severity Rating Scale(C-SSRS)

Time Frame: Up to Day 72

The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).

Change from Baseline of Barnes Akathisia Rating Scale (BARS) Results

Time Frame: Up to Day 72

Evaluating Extrapyramidal symptoms using the BARS. The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the subject, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.

Secondary Outcomes

  • Single-dose: Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)(Day 1)
  • Multiple-dose: Minimum blood plasma concentration (Cmin) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Apparent Total Clearance of Drug from plasma: CL/F for CVL-231(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Steady-state average plasma drug concentration: Css for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Accumulation ratio calculated from Cmax,ss and Cmax after single dosing (Rac, Cmax) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Accumulation ratio calculated from AUCτ,ss and AUCτ after single dosing (Rac, AUC) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Elimination half-life (t½) for CVL-231 and Metabolite (PF-06892787)(Day 14-17 and/or Day 28-31)
  • Single-dose: Area under the plasma concentration vs. time curve (AUC) for CVL-231 and Metabolite (PF-06892787)(Day 1)
  • Multiple-dose: Steady state CVL-231 Peak Plasma Concentration (Cmax) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Trough plasma concentration (Ctrough) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Peak Trough Ratio (PTR) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Renal clearance for parent only for CVL-231(Days 14 and/or 28)
  • Single-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)(Day 1)
  • Single-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)(Day 1)
  • Multiple-dose: Area under the plasma concentration-time curve (AUCτ) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)
  • Multiple-dose: Elimination rate constant (kel) for CVL-231 and Metabolite (PF-06892787)(Day 14-17 and/or Day 28-31)
  • Multiple-dose: Ae (amount eliminated unchanged in urine) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28)
  • Multiple-dose: Metabolite to parent ratio for Cmax for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28)
  • Multiple-dose: Metabolite to parent ratio for AUCtau for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28)
  • Single-dose: Metabolite to parent ratio for AUC tau for CVL-231 and Metabolite (PF-06892787)(Day 1)
  • Multiple-dose: Time to Maximum Concentration (Tmax) for CVL-231 and Metabolite (PF-06892787)(Days 14 and/or 28 and/or 36)

Study Sites (5)

Loading locations...

Similar Trials